+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A thalidomide analogue CC-4047 enhances anti-tumour immunity elicited by tumour cell vaccination



A thalidomide analogue CC-4047 enhances anti-tumour immunity elicited by tumour cell vaccination



Immunology 101(Supplement 1): 120




(PDF emailed within 1 workday: $29.90)

Accession: 034329922

Download citation: RISBibTeXText


Related references

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. British Journal of Cancer 78(3): 336-343, 1998

Cancer Cell Death-Inducing Radiotherapy: Impact on Local Tumour Control, Tumour Cell Proliferation and Induction of Systemic Anti-tumour Immunity. Advances in Experimental Medicine and Biology 930: 151-172, 2017

Studies in the enhancement of tumour immunity by coupling strong antigens to tumour cells ('heterogenization of tumours'). Helper T cell clones against PPD help other T cells mount anti-tumour responses to PPD-coupled tumour cells. Immunology 51(4): 755-763, 1984

The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. International Journal of Hyperthermia 29(5): 380-389, 2014

Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clinical and Experimental Immunology 170(2): 167-177, 2013

Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Research 18(6a): 4409-4413, 1999

Tube leukocyte adherence inhibition assay for the detection of anti-tumour immunity. II. Monocyte reacts with tumour antigen via cytophilic anti-tumour antibody. International Journal of Cancer 18(1): 48-57, 1976

Studies on the effector cell of anti-tumour immunity in a chemically induced mouse tumour system. British Journal of Cancer 31(2): 157-163, 1975

Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Clinical and Experimental Immunology 162(1): 75-83, 2010

Anti-theta serum-induced supression of the cellular transfer of tumour-specific immunity to a syngeneic plasma cell tumour. Nature: New Biology 238(82): 116-117, 1972

Local anergy rather than systemic anti-tumour immunity to explain tumour growth in an animal model of oral squamous cell carcinoma. Oncology Reports 4(5): 883-888, 1997

OP9-DL1 cell co-culture enhances anti-tumour immunity of mouse bone marrow-derived dendritic cells. Cell Biology International 36(3): 297-303, 2012

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. British Journal of Haematology 2019, 2019

Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model. British Journal of Radiology 84(998): 179-183, 2011

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. British Journal of Cancer 72(2): 339-343, 1995